Literature DB >> 10383817

Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells.

E M Hiltbold1, M D Alter, P Ciborowski, O J Finn.   

Abstract

We previously reported that the glycosylated MUC1 tumor antigen circulating as soluble protein in patients' serum is not processed by dendritic cells and does not elicit MHC-Class II-restricted T helper responses in vitro. In contrast, a long synthetic peptide from the MUC1 tandem repeat region is presented by Class II molecules, resulting in the initiation of T helper cell responses. Here we addressed the ability of dendritic cells to present various glycosylated or not glycosylated forms of MUC1 by MHC Class I. We found that three different forms of MUC1, ranging from glycosylated and underglycosylated protein to unglycosylated synthetic peptide, were able to elicit MUC1-specific, Class-I-restricted CTL responses. The efficiency of processing and the resulting strength of CTL activity were inversely correlated with the degree of glycosylation of the antigen. Furthermore, the more efficiently processed 100mer peptide primed a broader repertoire of CTL than the glycosylated protein. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383817     DOI: 10.1006/cimm.1999.1512

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  20 in total

1.  Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.

Authors:  Michael DeGregorio; Lin Soe; Michael Wolf
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

2.  MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.

Authors:  R L ten Berge; F G Snijdewint; S von Mensdorff-Pouilly; R J Poort-Keesom; J J Oudejans; J W Meijer; R Willemze; J Hilgers; C J Meijer
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

3.  Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses.

Authors:  Teresa Freire; Richard Lo-Man; Sylvie Bay; Claude Leclerc
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

4.  The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours.

Authors:  H Yang; N-H Cho; S-Y Seong
Journal:  Clin Exp Immunol       Date:  2009-07-17       Impact factor: 4.330

Review 5.  Human tumor antigens, immunosurveillance, and cancer vaccines.

Authors:  Olivera J Finn
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 6.  Tecemotide: an antigen-specific cancer immunotherapy.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael Wolf; Michael W DeGregorio
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.

Authors:  Eva Rossmann; Anders Österborg; Eva Löfvenberg; Aniruddha Choudhury; Ulf Forssmann; Anja von Heydebreck; Andreas Schröder; Håkan Mellstedt
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.

Authors:  Elizabeth Scheid; Pierre Major; Alain Bergeron; Olivera J Finn; Russell D Salter; Robin Eady; Bader Yassine-Diab; David Favre; Yoav Peretz; Claire Landry; Sebastien Hotte; Som D Mukherjee; Gregory A Dekaban; Corby Fink; Paula J Foster; Jeffery Gaudet; Jean Gariepy; Rafick-Pierre Sekaly; Louis Lacombe; Yves Fradet; Ronan Foley
Journal:  Cancer Immunol Res       Date:  2016-09-07       Impact factor: 11.151

9.  MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer.

Authors:  Alan Siroy; Fadi W Abdul-Karim; John Miedler; Nancy Fong; Pingfu Fu; Hannah Gilmore; Joseph Baar
Journal:  Hum Pathol       Date:  2013-07-08       Impact factor: 3.466

10.  Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.

Authors:  Caroline B Madsen; Cecilie Petersen; Kirstine Lavrsen; Mikkel Harndahl; Søren Buus; Henrik Clausen; Anders E Pedersen; Hans H Wandall
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.